Intervacc AB (publ) held its Annual General Meeting (”AGM”) on Wednesday 13 May 2026, at which the following resolutions were made.
Intervacc AB (publ), a Swedish growth company in animal health with the vaccine Strangvac® registered on 16 European markets, today announces that the company is strengthening its management team through the ... Read more
Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, highlights the annual initiative Strangles Awareness Week – an international awareness campaign aimed at reducing the spread of strangles ... Read more
Today, Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, together with Dechra Pharmaceuticals PLC, is hosting a European Key Opinion Leader (KOL) meeting focused on advancing best practice ... Read more
Intervacc AB (publ) announces that Strangvac®, the company’s innovative vaccine against strangles in horses, has been approved by the authorities in Iceland.
Strangles, a ... Read more